Malte Palm Suppli

Dr. Malte Palm Suppli


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Peptides
Verified
Journal Article
Open access
AEAnders Englund
Anders Englund
HGHannah Gilliam-Vigh
Hannah Gilliam-Vigh
MSMalte Palm Suppli
Malte Palm Suppli
LGLærke S. Gasbjerg
Lærke S. Gasbjerg
Tina VilsbøllTina Vilsbøll
Tina Vilsbøll
FKFilip Knop
Filip Knop

8 February 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
HGHannah Gilliam-Vigh
Hannah Gilliam-Vigh
MSMalte Palm Suppli
Malte Palm Suppli
SHSebastian Møller Nguyen Heimbürger
Sebastian Møller Nguyen Heimbürger
NSNikolaj Bach Sørum
Nikolaj Bach Sørum
FKFilip Knop
Filip Knop
AEAnne-Marie Ellegaard
Anne-Marie Ellegaard
Objective: Cholesin is a recently discovered gut-derived hormone secreted by enterocytes upon dietary cholesterol uptake via the transmembrane sterol transporter Niemann–Pick disease C1-like intracellular cholesterol transporter 1 (NPC1L1). In the liver, cholesin activates G protein-coupled receptor 146 (GPR146), causing reduced cholesterol synthesis. In this exploratory, hypothesis-generating study based on post hoc analysis, human data on the cholesin system are presented. Methods: Mucosal biopsies were collected throughout the intestinal tract from 12 individuals with type 2 diabetes (T2D) and 12 healthy, matched controls. Upper small intestinal mucosal biopsies were collected from 20 individuals before and after Roux-en-Y gastric bypass (RYGB) surgery. Liver biopsies were collected from 12 men with obesity and 15 matched controls without obesity. Subcutaneous abdominal adipose tissue biopsies were collected from 20 men with type 1 diabetes (T1D). All biopsies underwent full mRNA sequencing. Results: Cholesin mRNA expression was observed throughout the intestinal tracts of the individuals with T2D and the controls, in the livers of men with and without obesity, and in adipose tissue of men with T1D. NPC1L1 mRNA expression was robust throughout the small intestines but negligible in the large intestines of both individuals with and without T2D. RYGB surgery induced the expression of NPC1L1 mRNA in the upper small intestine. GPR146 mRNA was expressed in the livers of men, both with and without obesity, and in the adipose tissue of men with T1D, but not in the intestines. Conclusions: Our results suggest a role of the cholesin system in human physiology, but whether it is perturbed in metabolic diseases remains unknown. Clinical trial registration numbers: NCT03044860, NCT03093298, NCT02337660, NCT03734718.

23 August 2025 in Journal of the Endocrine Society
Verified
Journal Article
Open access
MSMalte Palm Suppli
Malte Palm Suppli
AHAstrid Høgedal
Astrid Høgedal
JBJonatan Ising Bagger
Jonatan Ising Bagger
MGMagnus Frederik Gluud Grøndahl
Magnus Frederik Gluud Grøndahl
JFJulie Forman
Julie Forman
FKFilip Krag Knop
Filip Krag Knop
Context: Amino acids are known to stimulate glucagon secretion, and most amino acids can elicit a glucagon response after IV administration. Recent studies have identified a feedback loop between the liver and pancreatic α cells, regulated by glucagon and circulating amino acids, termed the liver-α cell axis. Objective: We compared the glucagonotropic effects of amino acids suggested to drive the liver-α cell axis in humans. Methods: We recruited 12 healthy male participants for a double-blind, randomized study. Each participant received equimolar bolus injections of alanine, arginine, leucine, glutamine, proline, and saline (placebo) after an overnight fast on separate days. Results: Arginine significantly increased glucagon plasma concentrations compared to placebo, evaluated by the incremental area under the curve after 30 minutes ([mean ± SD] 133 ± 71 vs 34 ± 34 pmol/L × min) and the maximum concentration of glucagon after injection (44 ± 18 vs 15 ± 4 pmol/L) (P < .01 for both). Alanine injection resulted in a minor increase in the peak concentration of glucagon, while glutamine showed a nonsignificant trend toward increased glucagon secretion. Insulin secretion was significantly increased by injections of arginine, alanine, and glutamine, with leucine showing a nonsignificant trend. Conclusion: In the given experimental setting, arginine was identified as the most efficient stimulator of glucagon secretion. Arginine, alanine, and glutamine stimulated insulin secretion, with arginine eliciting the largest response. Our results indicate that arginine could be involved in regulating the liver-α cell axis in humans.

12 October 2024 in Life
Verified
Journal Article
Open access
PDF file
KMKatharina Maruszczak
Katharina Maruszczak
PKPia Koren
Pia Koren
KRKonrad Radzikowski
Konrad Radzikowski
TPThomas Pixner
Thomas Pixner
MSMalte Palm Suppli
Malte Palm Suppli
GTGabriel Torbahn
Gabriel Torbahn
Introduction: Health systems are confronted with not only the growing worldwide childhood obesity epidemic but also associated comorbidities. These subsequently cause variations in distinct metabolic pathways, leading to metabolic dysfunction-associated steatotic liver disease (MASLD). The aim of this evidence map is to systematically evaluate the evidence and to identify research gaps on glucagon-induced amino acid (AA) turnover and its metabolic interaction with MASLD. Methodology: A systematic literature search was conducted up to April 2023 in three electronic databases. Studies were required to include at least two of the main research areas, glucagon, AA metabolism and MASLD. Two independent reviewers screened titles and abstracts according to prespecified eligibility criteria, as well as full-text articles. Results are summarized in tables stratified by human and animal studies and study population age. Results: Thirty-four references were ultimately included. The publication years dated back to 1965 showed a great increase from 2012 to 2023. In total, there were 19 animal studies and 15 human studies. Among the human studies, except for two studies in adolescents, all the studies were conducted in adults. In human studies, the methods used to evaluate metabolic changes differed among hyperinsulinemic-euglycemic clamp and oral glucose tolerance tests. Thirteen studies focused on the metabolic effects of MASLD, while only two studies explored the interaction between MASLD, glucagon and AA metabolism in humans. The other 19 studies focused on metabolomics, beta cell function or just one topic of a research area and not on interactions between one another. Conclusion: Research on the interaction between MASLD, glucagon and AA metabolism in humans is sparse and complete lacking in pediatrics. Furthermore, longitudinal studies with a focus on hyperglucagonemia independent of diabetes but related to MASLD present an unambiguous research gap.